RxDoctor Payments Data

Jose Bonelli, MD

Internal Medicine · Silver Spring, MDNPI 1396829628

Payments from drug & device makers

$40,084in general payments, 2019–2025

Across 1,436 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$10K
  • Novo Nordisk$6K
  • AstraZeneca$4K
  • AbbVie$3K
  • Corcept Therapeutics$1K
  • Kowa Pharmaceuticals America, Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Consulting fees$5,25013%
  • Travel & lodging$2,6817%
  • Food & beverage$32,14180%
  • Education$120%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC100$9,946
Novo Nordisk301$5,617
AstraZeneca78$3,985
AbbVie(2 entities)170$3,150
Corcept Therapeutics52$1,348
Kowa Pharmaceuticals America, Inc.116$1,319
Amgen(2 entities)56$1,263
Boehringer Ingelheim48$1,094
Gilead38$1,070
Otsuka America Pharmaceutical, Inc.48$1,050
Pfizer38$864
Scilex Pharmaceuticals Inc.46$825
Johnson & Johnson(2 entities)20$698
Bayer24$687
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$640
Amarin Pharma, Inc.35$590
Merck25$586
Abbott22$582
E.r. Squibb & Sons, L.L.C.16$461
Arcutis Biotherapeutics, Inc.5$406
GSK9$289
Arbor Pharmaceuticals, Inc.24$267
Antares Pharma, Inc.6$267
Takeda Pharmaceuticals U.S.A., Inc.13$258
Grifols USA, LLC19$221
Exact Sciences9$197
Lundbeck LLC9$163
Novartis10$161
Axsome Therapeutics, Inc.2$144
Valeritas, Inc.4$135
Sanofi-aventis U.S. LLC7$131
Xeris Pharmaceuticals, Inc.6$129
Viiv Healthcare Company7$128
Noven Pharmaceuticals, Inc.1$125
Radius Health, Inc.1$123
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$107
Helsinn Therapeutics (U.S.), Inc.1$78
Aclaris Therapeutics, Inc.1$76
Endo USA, Inc.3$75
Azurity Pharmaceuticals, Inc.4$70
Dexcom, Inc.3$66
Alfasigma USA, Inc.3$56
Phadia US Inc.3$49
Endo Pharmaceuticals Inc.2$46
Sumitomo Pharma America, Inc.2$44
Lucira Health, Inc.2$43
Idorsia Pharmaceuticals US Inc2$38
ANI Pharmaceuticals, Inc.2$38
Actelion Pharmaceuticals US, Inc.1$31
Dynavax Technologies Corporation1$31
Hologic Sales And Service, LLC1$25
Sanofi Pasteur Inc.2$25
Ultragenyx Pharmaceutical Inc.1$23
Noven Therapeutics, LLC1$23
Halozyme Inc1$23
IBSA Pharma Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$21
Seqirus USA Inc1$20
Medtronic1$20
Recordati_rare_diseases_inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,084 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$235,805
Medicare patients
307
Services billed
4,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$132,428
FarxigaDapagliflozin Propanediol100$130,854
JardianceEmpagliflozin87$110,073
OtezlaApremilast14$78,672
RybelsusSemaglutide26$60,178
MounjaroTirzepatide32$48,930
EliquisApixaban45$47,382
RexultiBrexpiprazole28$45,863
JanuviaSitagliptin Phosphate32$42,132
ProliaDenosumab19$33,216
LinzessLinaclotide30$26,707
Tresiba Flextouch U-100Insulin Degludec46$22,966
VascepaIcosapent Ethyl43$22,328
TradjentaLinagliptin25$21,992
TrulicityDulaglutide11$20,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$5,617$192,606105 claims
Boehringer IngelheimJardiance, Tradjenta$1,094$132,065112 claims
AstraZenecaFarxiga$3,985$130,854100 claims
AmgenOtezla, Prolia$1,263$111,88833 claims
Lilly USA, LLCMounjaro, Trulicity$9,946$69,16443 claims
PfizerEliquis$864$47,38245 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,050$45,86328 claims
MerckJanuvia$586$42,13232 claims
AbbVieLinzess, Synthroid$3,150$28,84955 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$267$21,80433 claims
Scilex Pharmaceuticals Inc.Ztlido$825$19,47718 claims
NovartisEntresto$161$14,98413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →